Early Stage Non-small Cell Lung Cancer Clinical Trial
Official title:
Pathologic Effects of Neoadjuvant Radiation Therapy in Operable Early Stage Lung Cancer
Surgical resection with mediastinal lymph node sampling is currently the therapy of choice for early stage (I-II) non-small cell lung cancer (NSCLC). Selected patients unwilling or unable to tolerate surgery are referred for so-called 'curative' high dose radiotherapy. This has shown to result in a long term local disease control rate and a high cancer specific survival. The current trial addresses the relationship between blood and tissue biomarkers, bio-imaging and pathology in patients with early stage NSCLC treated with hypofractionated radiation therapy and surgery.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04530227 -
Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC
|
Phase 2 | |
| Terminated |
NCT03050554 -
Stereotactic Body Radiation Therapy (SBRT) Combined With Avelumab (Anti-PD-L1) for Management of Early Stage Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
| Completed |
NCT03916367 -
CT-guided Radioactive I-125 Seeds Implantation for Early Stage Lung Cancer
|
||
| Recruiting |
NCT03546829 -
Randomized Pilot Trial of Antimicrobial Therapy and Stereotactic Body Radiation Therapy in Early-stage Non-small Cell Lung Cancer
|
Early Phase 1 | |
| Recruiting |
NCT05785845 -
Computed Tomography-Guided Stereotactic Adaptive Radiotherapy (CT-STAR) for the Treatment of Central and Ultra-Central Early-Stage Non-Small Cell Lung Cancer
|
N/A |